Aaron Prosnitz

Aaron Prosnitz

Auto-generated profile, based on publicly available information

Aaron Prosnitz

Levine Children’s Hospital

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Pediatrics
Verified
Journal Article
Closed access
CDCarrie Daymont
Carrie Daymont
ANAshley Neal
Ashley Neal
APAaron Prosnitz
Aaron Prosnitz
MCMeryl S. Cohen
Meryl S. Cohen
OBJECTIVE: We sought to describe growth in young children with congenital heart disease (CHD) over time. METHODS: We performed a retrospective matched cohort study, identifying children with CHD in a large primary care network in Pennsylvania, New Jersey, and Delaware and matching them 10:1 with control subjects. The primary endpoint was the difference in mean World Health Organization z score for cases and controls for weight-for-age (WFAZ), length-for-age (LFAZ), weight-for-length (WFLZ), and head circumference-for-age (HCFAZ) at traditional ages for preventive visits, stratified by CHD category. RESULTS: We evaluated 856 cases: 37 with single ventricle (SV) physiology, 52 requiring complex repair (CR), 159 requiring simple repair (SR), and 608 requiring no repair. For children in the SV, CR, and SR categories, large, simultaneous, and statistically significant (Student’s t test P < .05) decreases in WFAZ and LFAZ appeared within the first month of life, peaked near 4 months, and persisted through 24 or 36 months. There were fewer and smaller decreases in the no-repair group between 2 and 18 months. HC data were available between 1 week and 24 months; at those ages, decreases in mean HCFAZ generally paralleled decreases in WFAZ and LFAZ in the SV, CR, and SR groups. CONCLUSIONS: Children with CHD experience early, simultaneous decreases in growth trajectory across weight, length, and head circumference. The simultaneous decrease suggests a role for altered growth regulation in children with CHD.

13 September 2006 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
LELisa Edelmann
Lisa Edelmann
APAaron Prosnitz
Aaron Prosnitz
SPSherly Pardo
Sherly Pardo
JBJahnavi Bhatt
Jahnavi Bhatt
NCNinette Cohen
Ninette Cohen
LML Alison McInnes
L Alison McInnes
Background: During a genetic study of autism, a female child who met diagnostic criteria for autism spectrum disorder, but also exhibited the cognitive–behavioural profile (CBP) associated with Williams–Beuren syndrome (WBS) was examined. The WBS CBP includes impaired visuospatial ability, an overly friendly personality, excessive non-social anxiety and language delay. Methods: Using array-based comparative genomic hybridisation (aCGH), a deletion corresponding to BAC RP11-89A20 in the distal end of the WBS deletion interval was detected. Hemizygosity was confirmed using fluorescence in situ hybridisation and fine mapping was performed by measuring the copy number of genomic DNA using quantitative polymerase chain reaction. Results: The proximal breakpoint was mapped to intron 1 of GTF2IRD1 and the distal breakpoint lies 2.4–3.1 Mb towards the telomere. The subject was completely hemizygous for GTF2I, commonly deleted in carriers of the classic ∼1.5 Mb WBS deletion, and GTF2IRD2, deleted in carriers of the rare ∼1.84 Mb WBS deletion. Conclusion: Hemizygosity of the GTF2 family of transcription factors is sufficient to produce many aspects of the WBS CBP, and particularly implicate the GTF2 transcription factors in the visuospatial construction deficit. Symptoms of autism in this case may be due to deletion of additional genes outside the typical WBS interval or remote effects on gene expression at other loci.

13 February 2018 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
APAaron R. Prosnitz
Aaron R. Prosnitz
MDMonika Drogosz
Monika Drogosz
AMAudrey C. Marshall
Audrey C. Marshall
LWLouise E. Wilkins‐Haug
Louise E. Wilkins‐Haug
CBCarol B. Benson
Carol B. Benson
KFKevin G. Friedman
Kevin G. Friedman

1 January 2013 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
APAaron R. Prosnitz
Aaron R. Prosnitz
MLMary B. Leonard
Mary B. Leonard
JSJustine Shults
Justine Shults
BZBabette S. Zemel
Babette S. Zemel
BHBruce W. Hollis
Bruce W. Hollis
MTMeena Thayu
Meena Thayu

1 August 2023 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Open access
EMEmanuele Monda
Emanuele Monda
APAaron Prosnitz
Aaron Prosnitz
RARossella Aiello
Rossella Aiello
MLMichele Lioncino
Michele Lioncino
GNGabrielle Norrish
Gabrielle Norrish
Giuseppe LimongelliGiuseppe Limongelli
Giuseppe Limongelli
BACKGROUND: We aimed to examine clinical features and outcomes of consecutive molecularly characterized patients with Noonan syndrome with multiple lentigines and hypertrophic cardiomyopathy. METHODS: A retrospective, longitudinal multicenter cohort of consecutive children and adults with a genetic diagnosis of Noonan syndrome with multiple lentigines and hypertrophic cardiomyopathy between 2002 and 2019 was assembled. We defined a priori 3 different patterns of left ventricular remodeling during follow-up: (1) an increase in ≥15% of the maximal left ventricular wall thickness (MLVWT), both in mm and z -score (progression); (2) a reduction ≥15% of the MLVWT, both in mm and z -score (absolute regression); (3) a reduction ≥15% of the MLVWT z -score with a stable MLVWT in mm (relative regression). The primary study end point was a composite of cardiovascular death, heart transplantation, and appropriate implantable cardioverter defibrillator-shock. RESULTS: The cohort comprised 42 patients with Noonan syndrome with multiple lentigines and hypertrophic cardiomyopathy, with a median age at diagnosis of 3.5 (interquartile range, 0.2–12.3) years. Freedom from primary end point was 92.7% (95% CI, 84.7%–100%) 1 year after presentation and 80.9% (95% CI, 70.1%–90.7%) at 5 years. Patients with MLVWT z -score >13.7 showed reduced survival compared with those with <13.7. During a median follow-up of 3.7 years (interquartile range, 2.6–7.9), absolute regression was the most common type of left ventricular remodeling (n=9, 31%), followed by progression (n=6, 21%), and relative regression (n=6, 21%). CONCLUSIONS: These findings provide insights into the natural history of left ventricular hypertrophy, and can help inform clinicians regarding risk stratification and clinical outcomes in patients with Noonan syndrome with multiple lentigines and hypertrophic cardiomyopathy.

18 July 2017 in Congenital Heart Disease
Verified
Journal Article
Closed access
PDF file
APAaron R. Prosnitz
Aaron R. Prosnitz
JLJane Leopold
Jane Leopold
MIMira Irons
Mira Irons
KJKathy Jenkins
Kathy Jenkins
ARAmy Roberts
Amy Roberts
Objective To describe a group of children with co‐incident pulmonary vein stenosis and Smith‐Lemli‐Opitz syndrome and to generate hypotheses as to the shared pathogenesis of these disorders. Design Retrospective case series. Patients Five subjects in a pulmonary vein stenosis cohort of 170 subjects were diagnosed with Smith‐Lemli‐Opitz syndrome soon after birth. Results All five cases were diagnosed with Smith‐Lemli‐Opitz syndrome within 6 weeks of life, with no family history of either disorder. All cases had pathologically elevated 7‐dehydrocholesterol levels and two of the five cases had previously reported pathogenic 7‐dehydrocholesterol reductase mutations. Smith‐Lemli‐Opitz syndrome severity scores ranged from mild to classical (2–7). Gestational age at birth ranged from 35 to 39 weeks. Four of the cases were male by karyotype. Pulmonary vein stenosis was diagnosed in all cases within 2 months of life, earlier than most published cohorts. All cases progressed to bilateral disease and three cases developed atresia of at least one vein. Despite catheter and surgical interventions, all subjects' pulmonary vein stenosis rapidly recurred and progressed. Three of the subjects died, at 2 months, 3 months, and 11 months. Survival at 16 months after diagnosis was 43%. Conclusions Patients with pulmonary vein stenosis who have a suggestive syndromic presentation should be screened for Smith‐Lemli‐Opitz syndrome with easily obtainable serum sterol tests. Echocardiograms should be obtained in all newly diagnosed patients with Smith‐Lemli‐Opitz syndrome, with a low threshold for repeating the study if new respiratory symptoms of uncertain etiology arise. Further studies into the pathophysiology of pulmonary vein stenosis should consider the role of cholesterol‐based signaling pathways in the promotion of intimal proliferation.